HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy

Blood

Volumn 123, Issue 19, 2014, Pages 2924-2933

  Fajgenbaum, David C ^a   Van Rhee, Frits ^b   Nabel, Christopher S ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; AUTACOID;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CLINICAL FEATURE; CYTOKINE RELEASE; CYTOKINE STORM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SECRETORY CELL; BIOLOGICAL MODEL; BLOOD; GIANT LYMPH NODE HYPERPLASIA; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY;

CYTOKINES; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL;

EID: 84900445271     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-545087     Document Type: Review

References (100)

1. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16 (4): 236-246.
2. Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013;53 (1):69-77.
3. Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol. 2012;24 (1): 76-83.
4. Mehra M, Cossrow N, Stellhorn RA, Vermeulen J, Desai A, Munshi NC. Use of a claims database to characterize and estimate the incidence of Castleman's disease [abstract]. Blood. 2012; 120 (21). Abstract 4253.
5. Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDSassociated multicentric Castleman's disease. Pathol Int. 2001;51 (9):671-679. (Pubitemid 32989612)
6. Dossier A, Meignin V, Fieschi C, Boutboul D, Oksenhendler E, Galicier L. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis. 2013;56 (6): 833-842.
7. Leroy S, Moshous D, Cassar O, et al. Multicentric Castleman disease in an HHV8- infected child born to consanguineous parents with systematic review. Pediatrics. 2012;129 (1): e199-e203.
8. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22 (5): 347-352.
9. Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16 (9):1316-1324.
10. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. Am J Hematol. 2012;87 (11):997-1002.
11. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20 (6): 636-647. (Pubitemid 24015203)
12. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti- IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013; 19 (13):3659-3670.
13. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106 (8):2627-2632. (Pubitemid 41510733)
14. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8 (7): 486-498.
15. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010; 116 (22):4415-4421.
16. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis. 1997; 175 (5):1198-1201.
17. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 1954;251 (10): 396-400.
18. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69 (1):86-90. (Pubitemid 8269654)
19. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43 (8): 698-704. (Pubitemid 40066010)
20. Menke DM, DeWald GW. Lack of cytogenetic abnormalities in Castleman's disease. South Med J. 2001;94 (5):472-474. (Pubitemid 33643473)
21. Weisenburger DD. Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen. Am J Surg Pathol. 1988;12 (3): 176-181. (Pubitemid 18085201)
22. Kojima M, Motoori T, Asano S, Nakamura S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007;203 (6):423-431. (Pubitemid 46852314)
23. Kojima M, Motoori T, Nakamura S. Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother. 2006;60 (10):663-672. (Pubitemid 44822653)
24. Kojima M, Nakamura S, Morishita Y, et al. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int. 2000;50 (4):304-312. (Pubitemid 30441282)
25. Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol. 1994;101 (3):290-295. (Pubitemid 24089574)
26. Al-Maghrabi J, Kamel-Reid S, Bailey D. Immunoglobulin and T-cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis. Histopathology. 2006;48 (3):233-238.
27. Nakamura H, Nakaseko C, Ishii A, et al. [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6]. Rinsho Ketsueki. 1993;34 (2):212-217.
28. Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol. 2013.
29. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129 (1):3-17. (Pubitemid 40524047)
30. Fajgenbaum D, Rosenbach M, van Rhee F, Nasir A, Reutter J. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA Dermatol. 2013;149 (2):204-208.
31. Ahmed B, Tschen JA, Cohen PR, et al. Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther. 2007; 6 (9):2386-2390. (Pubitemid 47480403)
32. Zhai S. Polynesian variant of idiopathic multicentric Castleman disease [abstract]. Blood. 2013;122 (21). Abstract 5127.
33. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53 (1):57-61.
34. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984;34 (6):712-720. (Pubitemid 14107067)
35. Soubrier MJ, Dubost JJ, Sauvezie BJ; French Study Group on POEMS Syndrome. POEMS syndrome: a study of 25 cases and a review of the literature. Am J Med. 1994;97 (6):543-553. (Pubitemid 24370886)
36. Morishima A, Marui A, Shimamoto T, Saji Y, Nishina T, Komeda M. A case of interleukin- 6-producing cardiac myxoma resembling multicentric Castleman's disease. J Thorac Cardiovasc Surg. 2009;138 (2):499-501.
37. Stone K, Woods E, Szmania SM, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS ONE. 2013; 8 (1):e54610.
38. Barozzi P, Luppi M, Masini L, et al. Lymphotropic herpes virus (EBV, HHV-6, HHV-8) DNA sequences in HIV negative Castleman's disease. Clin Mol Pathol. 1996;49 (4):M232-M235.
39. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999;85 (3): 706-717. (Pubitemid 29075292)
40. Chen CH, Liu HC, Hung TT, Liu TP. Possible roles of Epstein-Barr virus in Castleman disease. J Cardiothorac Surg. 2009;4:31.
41. Jones EL, Crocker J, Gregory J, Guibarra M, Curran RC. Angiofollicular lymph node hyperplasia (Castleman's disease): an immunohistochemical and enzymehistochemical study of the hyaline-vascular form of lesion. J Pathol. 1984;144 (2):131-147. (Pubitemid 15202425)
42. Murray PG, Deacon E, Young LS, et al. Localization of Epstein-Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry. Hematol Pathol. 1995; 9 (1):17-26.
43. Yuan XG, Chen FF, Zhu YM, Hu W, Zhao XY, Jin J. High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease. Ann Hematol. 2012;91 (6):857-861.
44. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28 (23):3701-3708.
45. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990;86 (2): 592-599. (Pubitemid 20271895)
46. Katsume A, Saito H, Yamada Y, et al. Antiinterleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 2002;20 (6): 304-311. (Pubitemid 36299051)
47. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995;14 (9):1932-1941.
48. Momoi A, Kojima M, Sakai T, et al. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case. Int J Hematol. 2013;97 (2): 275-279.
49. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61 (4):428-437. (Pubitemid 351518223)
50. van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994;84 (5):1434-1441.
51. Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology. 1989; 14 (4):333-346, discussion 429-432. (Pubitemid 19129375)
52. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105 (3): 268-276. (Pubitemid 26077366)
53. Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia - a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53 (1):79-85.
54. Gherardi RK, Bélec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood. 1994;83 (9):2587-2593.
55. Lee M, Hirokawa M, Matuoka S, et al. Multicentric Castleman's disease with an increased serum level of macrophage colonystimulating factor. Am J Hematol. 1997;54 (4): 321-323. (Pubitemid 27160865)
56. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999; 104 (3):482-485. (Pubitemid 29119270)
57. Wang X, Ye S, Xiong C, Gao J, Xiao C, Xing X. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol. 2011;41 (10): 1221-1224.
58. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
59. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991;78 (11): 2923-2930.
60. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther. 2010;9 (6):1485-1488.
61. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16 (4):497-511.
62. De Marchi G, De Vita S, Fabris M, Scott CA, Ferraccioli G. Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature. Haematologica. 2004;89 (4):ECR03.
63. Ishii T, Tatekawa T, Koseto M, et al. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5. Eur J Haematol. 2003;70 (2): 115-118. (Pubitemid 36269558)
64. Ishiyama T, Nakamura S, Akimoto Y, et al. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease. Br J Haematol. 1994; 86 (3):483-489. (Pubitemid 24199035)
65. Liu J, Han S, Ding J, Wu K, Miao J, Fan D. COX2-related multicentric mixed-type Castleman's disease in a young man. Nat Clin Pract Oncol. 2005;2 (7):370-375, quiz 376. (Pubitemid 43118124)
66. Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A. Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res. 2009; 15 (3):375-381.
67. Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol. 2003;34 (9): 835-840. (Pubitemid 37169611)
68. Takubo T, Ohkura H, Kumura T, et al. Lymphoma in Castleman's disease, acute lymphocytic leukemia, adult T-cell leukemia and cutaneous T-cell lymphoma accompanied with high serum soluble Fas ligand levels. Haematologia (Budap). 2000;30 (1):23-26.
69. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621-668.
70. Alonzi T, Gorgoni B, Screpanti I, Gulino A, Poli V. Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation. Immunobiology. 1997;198 (1-3):144-156. (Pubitemid 28021390)
71. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102 (7):1369-1376. (Pubitemid 28467565)
72. Hatemi G, Masatlioglu S, Gogus F, Ozdogan H. Necrotizing vasculitis associated with familial Mediterranean fever. Am J Med. 2004;117 (7): 516-519. (Pubitemid 39349590)
73. Koné-Paut I, Hentgen V, Guillaume-Czitrom S, Compeyrot-Lacassagne S, Tran TA, Touitou I. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford). 2009;48 (7):840-842.
74. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal antiinterleukin- 6 antibody. N Engl J Med. 1994; 330 (9):602-605. (Pubitemid 24065794)
75. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989; 74 (4):1360-1367. (Pubitemid 19227448)
76. Lai YM, Li M, Liu CL, et al. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease]. Zhonghua Xue Ye Xue Za Zhi. 2013;34 (5):404-408.
77. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66 (2): 605-612. (Pubitemid 43165918)
78. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139 (6): 713-727.
79. Larroche C, Cacoub P, Soulier J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69 (2): 119-126. (Pubitemid 34111164)
80. Maione D, Di Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17 (19):5588-5597. (Pubitemid 28445970)
81. Zhu C-G, Zhang Q-Z, Zhu M, et al. A case report of syndrome of inappropriate antidiuretic hormone secretion with Castleman's disease and lymphoma. BMC Endocr Disord. 2013;13 (1):19.
82. Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N. Epstein-Barr virusimmortalized B cells produce IL-6 as an autocrine growth factor. Immunology. 1990; 70 (1):100-105. (Pubitemid 20148070)
83. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985; 3 (9):1202-1216. (Pubitemid 15226525)
84. Tsukamoto Y, Hanada N, Nomura Y, et al. Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol. 1991;11 (5):430-436.
85. Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin a : a case report. J Clin Exp Hematop. 2013;53 (1):95-99.
86. Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. J Clin Exp Hematop. 2013;53 (1): 63-68.
87. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003; 82 (12):766-768. (Pubitemid 38008844)
88. Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol. 2006;76 (2): 119-123.
89. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005; 78 (4):302-305. (Pubitemid 40471124)
90. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92 (3):670-676. (Pubitemid 32735205)
91. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128 (8):657-662. (Pubitemid 28169643)
92. Williams SC. First IL-6-blocking drug nears approval for rare blood disorder. Nat Med. 2013; 19 (10):1193.
93. Wong R, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebocontrolled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease [abstract]. Blood. 2013; 122 (21). Abstract 505.
94. Hess G, Wagner V, Kreft A, Heussel CP, Huber C. Effects of bortezomib on proinflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol. 2006; 134 (5):544-545. (Pubitemid 44141721)
95. Khan AA, Siraj F, Bhargava M, Aggarwal S. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib. BMJ Case Rep; bcr-2012.
96. Sobas MA, Alonso Vence N, Diaz Arias J, Bendanä Lopez A, Fraga Rodriguez M, Bello Lopez JL. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCDPOEMS variant). Ann Hematol. 2010;89 (2): 217-219.
97. Juvekar A, Manna S, Ramaswami S, et al. Bortezomib induces nuclear translocation of IkBa resulting in gene-specific suppression of NF-kB - dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res. 2011; 9 (2):183-194.
98. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26 (11): 2326-2335.
99. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol. 2006;81 (4):303-304.
100. Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol. 2008;30 (12):920-924.